HLX70
/ Fosun Pharma, ZJ Bio-Tech
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
September 03, 2022
Exploring the Binding Affinity and Mechanism between ACE2 and the Trimers of Delta and Omicron Spike Proteins by Molecular Dynamics Simulation and Bioassay.
(PubMed, J Chem Inf Model)
- "The experimentally determined K values by biolayer interferometry (BLI) and the predicted binding free energies of the RBDs of Delta and Omicron to mAb HLX70 revealed that the two variants may have the high risk of immune evasion from the mAb. These results are not only helpful in understanding the binding strength and mechanism of S protein trimer-ACE2 but also beneficial for drug, especially for antibody development."
Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
June 23, 2022
Evaluate Safety and Pharmacokinetics of HLX70 in Healthy Adult Volunteers
(clinicaltrials.gov)
- P1 | N=0 | Withdrawn | Sponsor: Shanghai Henlius Biotech
New P1 trial • Infectious Disease • Novel Coronavirus Disease
April 01, 2022
Evaluate Safety and Pharmacokinetics of HLX70 in Healthy Adult Volunteers
(clinicaltrials.gov)
- P1 | N=0 | Withdrawn | Sponsor: Hengenix Biotech Inc | N=24 ➔ 0 | Not yet recruiting ➔ Withdrawn
Enrollment change • Trial withdrawal • Infectious Disease • Novel Coronavirus Disease
September 23, 2020
Evaluate Safety and Pharmacokinetics of HLX70 in Healthy Adult Volunteers
(clinicaltrials.gov)
- P1; N=24; Not yet recruiting; Sponsor: Hengenix Biotech Inc
Clinical • New P1 trial • Infectious Disease • Novel Coronavirus Disease
1 to 4
Of
4
Go to page
1